Longevity biotech
Pilotmomentum 45902 papers in 3 months (+26% yearly)$1.1B raised in 12 months22 companies
Drugs and therapies that target the biology of aging itself to delay or reverse age-related decline and disease.
Why pilot: Life Biosciences dosed the first patient with ER-100, a partial epigenetic reprogramming therapy, in a Phase 1 trial. Jun 9, 2026
Dots under a month: dated events tracked here that month.
26 events
About longevity biotech here
- Sub-areas
- Partial epigenetic reprogramming, Senolytics and senescence, Autophagy and metabolic aging, Aging clocks and biomarkers, AI-driven aging drug discovery, Cell therapy and iPSC rejuvenation, Veterinary longevity drugs
- Stage evidence
- Pilot, Jun 9, 2026: Life Biosciences dosed the first patient with ER-100, a partial epigenetic reprogramming therapy, in a Phase 1 trial. lifebiosciences.com
- Momentum
- 45 of 100: the mean of its ranks among the tracked fields for paper growth (63), funding in 12 months (38) and events in 90 days (34). Method
- Papers
- 3,417 in the 12 months ending two months ago, +26% against the 12 before (OpenAlex topics, journal and conference papers).
- Tracked here since
- Sep 25, 2026
Changes to this field
| Date | Change | ||
|---|---|---|---|
| Sep 25, 2026 | Longevity biotechTechnology: Added | seed | lifebiosciences.com |